<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Musculoskelet Disord</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Musculoskelet Disord</journal-id>
      <journal-title-group>
        <journal-title>BMC Musculoskeletal Disorders</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2474</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26867651</article-id>
      <article-id pub-id-type="pmc">4751753</article-id>
      <article-id pub-id-type="publisher-id">926</article-id>
      <article-id pub-id-type="doi">10.1186/s12891-016-0926-x</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Tian</surname>
            <given-names>Yiming</given-names>
          </name>
          <address>
            <email>ming9er@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Rui</given-names>
          </name>
          <address>
            <email>sljwr@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Lianyuan</given-names>
          </name>
          <address>
            <email>qhdliulianyuan@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>Chunming</given-names>
          </name>
          <address>
            <email>machunming80@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lu</surname>
            <given-names>Qiang</given-names>
          </name>
          <address>
            <email>luqiangtg@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Yin</surname>
            <given-names>Fuzai</given-names>
          </name>
          <address>
            <email>yinfuzai62@sina.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Endocrinology, The First Hospital of Qinhuangdao, Hebei, China </aff>
        <aff id="Aff2"><label/>Liaison Office, the First Hospital of Qinhuangdao, Hebei, China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>2</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>11</day>
        <month>2</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>17</volume>
      <elocation-id>72</elocation-id>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>6</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>2</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Tian et al. 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Zoledronic acid-induced uveitis (ZAIU) is rare but severe, and has been recently considered part of an acute phase reaction. Only 15 cases have been reported since 2005. Here we describe a case with macular edema, which is the first reported case observed after long-term alendronate tolerance.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 63-year-old Asian woman received her first intravenous zoledronic acid treatment for the management of postmenopausal osteoporosis as a more convenient substitute for oral alendronate. Twenty-four hours later, bilateral eye irritations, periorbital swelling, blurred vision, and diplopia presented. The complete blood count and transaminase levels were normal, but the erythrocytic sedimentation, C-reactive protein, and serum C4 levels were elevated. On detailed ophthalmological examination, a diagnosis of bilateral acute uveitis and macular edema in the right eye was made. The ocular symptoms were not improved until administration of topical and oral steroids. Complete resolution was achieved. There was no rechallenge of bisphosphonates, and no recurrence at 6&#xA0;months follow-up. Based on an extensive review, abnormal fundus is rarely reported, especially in cases of macular edema. Rechallenge with zoledronic acid in five cases induced no additional uveitis, and changing the medication to pamidronate in another patient was also tolerated. Interestingly, our patient suffered from uveitis soon after intravenous zoledronate exposure after a two-year tolerance to oral alendronate.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>This is the first report of zoledronic acid induced uveitis with macular edema after long-term alendronate tolerance. Prior oral alendronate may not entirely prevent ZAIU. Steroids are usually necessary in the treatment of ZAIU. Bisphosphonate rechallenge is not fully contraindicated, and prior steroid administration may be a more reasonable treatment choice according to the available evidence.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Zoledronic acid</kwd>
        <kwd>Alendronate</kwd>
        <kwd>Bisphosphonate</kwd>
        <kwd>Uveitis</kwd>
        <kwd>Osteoporosis</kwd>
        <kwd>Macular edema</kwd>
        <kwd>Acute phase reaction</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p>Zoledronic acid is generally well-tolerated in the management of osteoporosis and other metabolic bone diseases [<xref ref-type="bibr" rid="CR1">1</xref>]. The most frequent adverse event is acute phase reaction (APR), which occurs in nearly half of the patients after zoledronate infusion, but usually lasts for a short time with less severity [<xref ref-type="bibr" rid="CR2">2</xref>]. Zoledronic acid-induced uveitis (ZAIU) is rare; the incidence was reported to be 0.8&#x2013;1.1&#xA0;% [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Some severe cases have presented with transient reduced visual acuity [<xref ref-type="bibr" rid="CR5">5</xref>&#x2013;<xref ref-type="bibr" rid="CR14">14</xref>]. Previously, other bisphosphonates (pamidronate [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], alendronate [<xref ref-type="bibr" rid="CR17">17</xref>], and clodronate [<xref ref-type="bibr" rid="CR18">18</xref>]) have also been reported to be associated with acute uveitis. Uveitis is not commonly considered to be part of the APR, but they occur within the same time frame, suggesting that it may have a similar pathogenesis [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Stepwise regression of a phase three clinical trial showed less APR after zoledronate infusion in previous users of oral bisphosphonates [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
      <p>Due to the low incidence [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], even a prospective randomized study failed to document the risk factors of ZAIU [<xref ref-type="bibr" rid="CR3">3</xref>]. Presently, only 15 individual cases have been reported [<xref ref-type="bibr" rid="CR5">5</xref>&#x2013;<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR22">22</xref>&#x2013;<xref ref-type="bibr" rid="CR25">25</xref>]. We describe a case accompanied with right macular edema occurring during the management of postmenopausal osteoporosis with the substitution of the more convenient orally administered alendronate. To our knowledge, this is the first report of ZAIU with macular edema, as well as the first report of ZAIU after long-term alendronate tolerance.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <sec id="Sec3">
        <title>Case report</title>
        <p>A 63-year-old Asian woman received her first dose of zoledronic acid (Aclasta&#xAE;, 5&#xA0;mg/100&#xA0;mL solution; Novartis, San Mateo, CA, USA) for postmenopausal osteoporosis. She suffered from a past hepatitis B virus infection. In the past 2&#xA0;years, she was on oral alendronate (70&#xA0;mg, once per week), and the patient regularly used calcium and vitamin D supplements. Slit-lamp and fundoscopy examinations before the application of zoledronic acid revealed right epiretinal membrane and bilateral xerophthalmia. Twenty-four hours after the infusion (5&#xA0;mg in 100&#xA0;mL normal saline over 15&#xA0;min at a constant infusion rate), she began experiencing multiple symptoms, including fatigue and weakness, generalized aches and pains, bilateral eye irritation, periorbital swelling, blurred vision, and diplopia.</p>
        <p>Upon examination, her best-corrected visual acuity was 20/40 in the left eye and 20/60 in the right eye, and her intraocular pressure was 17&#xA0;mm Hg, bilaterally. Slit-lamp examination revealed conjunctival hyperemia, ciliary injection, flare (2+), keratic precipitates (&#xB1;), and trace cells in the anterior chamber. Posterior synechiae was also present. Fundus and optical coherence tomography (OCT) examinations revealed right macular edema (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>), and fluorescein angiography showed hyperfluorescence of the optic disk. Hematological exams of complete blood counts and transaminase levels were normal. The erythrocyte sedimentation was 95&#xA0;mm/h, the C-reactive protein was elevated to 2.69&#xA0;mg/dL, and the serum C4 level was slightly increased to 0.45&#xA0;g/L. Bilateral acute uveitis was diagnosed and topical ganciclovir, pranoprofen, fluorometholone, and atropine were prescribed. Two days later, the ocular symptoms worsened, and treatment with retrobulbar injection of methylprednisolone and oral prednisolone was started. The patient&#x2019;s ocular symptoms improved remarkably in the following 3&#xA0;days, when best-corrected visual acuity reestablished to 20/30 bilaterally, and flare, keratic precipitates, cells, and macular edema disappeared. The patient continued with oral prednisolone, tapering slowly over the following 6&#xA0;weeks. She achieved complete resolution, with no rechallenge and no recurrence at the 6&#xA0;month follow-up.<fig id="Fig1"><label>Fig. 1</label><caption><p>Optical coherence tomography examinations revealed right macular edema in a postmenopausal women with ZAIU. Two days after the intravenous administration of zoledronic acid, the examination of optical coherence tomography (OCT) revealed right macular edema with epiretinal membrane (arrow) and a normal left macula</p></caption><graphic xlink:href="12891_2016_926_Fig1_HTML" id="MO1"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec4">
      <title>Discussion</title>
      <p>According to the Naranjo adverse drug reaction probability scale, in our case study a score of 8 indicates a probable association between zoledronic acid and uveitis. Regarding previously published cases, a probable [<xref ref-type="bibr" rid="CR10">10</xref>] to definite [<xref ref-type="bibr" rid="CR5">5</xref>] causality has been reported.</p>
      <p>The National Osteoporosis Foundation (NOF) recommends that any eye inflammation related to bisphosphonate should be reported to the healthcare provider as soon as possible [<xref ref-type="bibr" rid="CR26">26</xref>]. However, due to the low prevalence and lack of recognition, although recommended by an ophthalmologist, the correct diagnosis was made 2&#xA0;days after the onset of eye irritations, which worsened the ocular symptoms of our patient, and eye drops of antivirals were inappropriately prescribed. Fortunately, all the ocular manifestations recovered promptly, including the right macular edema.</p>
      <p>Clinical features of 16 published cases (including our case) with ZAIU are shown in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. Eight cases suffered from osteoporosis (including our case) [<xref ref-type="bibr" rid="CR5">5</xref>&#x2013;<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], four with bone metastasis from malignant tumors [<xref ref-type="bibr" rid="CR9">9</xref>&#x2013;<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], one with frontal hyperostosis and breast cancer [<xref ref-type="bibr" rid="CR25">25</xref>], one with back and femur pain from the treatment of monoclonal gammopathy of undetermined significance (MGUS) [<xref ref-type="bibr" rid="CR14">14</xref>], and the remaining two cases had risks of osteopenia due to leuprolide treatment for prostate cancer [<xref ref-type="bibr" rid="CR12">12</xref>]. All the ocular manifestations occurred in 3&#xA0;days. Only two out of 16 patients had a past ocular history. Bilateral eye involvement appeared in one-third of the patients, corresponding to a previous study [<xref ref-type="bibr" rid="CR8">8</xref>]. The main ocular symptoms and signs included eye pain, blurred vision, diplopia, photophobia, lid edema, proptosis, conjunctival chemosis, hyperemia, and ophthalmoplegia. Nearly half of the patients presented with systemic symptoms. Posterior synechiae was observed in 6 patients, and most of the cases were cured. Choroidal folds [<xref ref-type="bibr" rid="CR6">6</xref>] and vitreous haze [<xref ref-type="bibr" rid="CR5">5</xref>] presented in some unusual cases. However, abnormal fundus was rarely reported, especially macular edema, as described in our case.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical features of the 16 published cases (including our case) with zoledronic acid induced uveitis</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Case</th><th>Age</th><th>Eye involved</th><th>Time from exposure to onset of ocular menifestations</th><th>Indications</th><th>Ocular history</th></tr></thead><tbody><tr><td>1 [<xref ref-type="bibr" rid="CR5">5</xref>]</td><td>66</td><td>unilateral</td><td>2d</td><td>postmenopausal osteoporosis</td><td>no</td></tr><tr><td>2 [<xref ref-type="bibr" rid="CR6">6</xref>]</td><td>75</td><td>unilateral</td><td>2d</td><td>osteoporosis</td><td>no</td></tr><tr><td>3 [<xref ref-type="bibr" rid="CR7">7</xref>]</td><td>58</td><td>unilateral</td><td>NA</td><td>osteoporosis</td><td>no</td></tr><tr><td>4 [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td>58</td><td>unilateral</td><td>10&#xA0;h</td><td>osteoporosis</td><td>no</td></tr><tr><td>5 [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td>56</td><td>unilateral</td><td>12&#xA0;h</td><td>postmenopausal osteoporosis</td><td>no</td></tr><tr><td>6 [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td>70</td><td>unilateral</td><td>1d</td><td>frontal hyperostosis after breast cancer</td><td>no</td></tr><tr><td>7 [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>54</td><td>bilateral</td><td>1d</td><td>breast cancer with bone matastasis</td><td>no</td></tr><tr><td>8 [<xref ref-type="bibr" rid="CR9">9</xref>]</td><td>78</td><td>unilateral</td><td>48&#xA0;h</td><td>prostate cancer with bone matastasis</td><td>no</td></tr><tr><td>9 [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td>48</td><td>unilateral</td><td>24&#xA0;h</td><td>breast cancer with bone matastasis</td><td>no</td></tr><tr><td>10 [<xref ref-type="bibr" rid="CR11">11</xref>]</td><td>54</td><td>unilateral</td><td>3d</td><td>breast cancer with lung and bone matastasis</td><td>no</td></tr><tr><td>11 [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td>56</td><td>bilateral</td><td>72&#xA0;h</td><td>prostate cancer treated with leuprolide</td><td>no</td></tr><tr><td>12 [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td>68</td><td>bilateral</td><td>60&#xA0;h</td><td>prostate cancer treated with leuprolide</td><td>no</td></tr><tr><td>13 [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td>60</td><td>unilateral</td><td>24&#xA0;h</td><td>osteoporosis and breast cancer</td><td>yes</td></tr><tr><td>14 [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td>62</td><td>bilateral</td><td>48&#xA0;h</td><td>back and femur pain in MGUS</td><td>no</td></tr><tr><td>15 [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td>59</td><td>unilateral</td><td>2d</td><td>osteoporosis</td><td>no</td></tr><tr><td>16<sup>a</sup>
</td><td>63</td><td>bilateral</td><td>24&#xA0;h</td><td>postmenopausal osteoporosis</td><td>yes</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>The case described in this report, <italic>NA</italic> not available, <italic>MGUS</italic> monoclonal gammopathy of undetermined significance</p></table-wrap-foot></table-wrap></p>
      <p>Corticosteroids are usually necessary for treatment. Topical steroids and adequate treatment often lead in most cases to full recovery, but a small portion of patients only respond well to systemic use of steroids [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. No deterioration of osteoporosis has been reported to be related with steroid treatment.</p>
      <p>Further use of bisphosphonates is not fully contraindicated. From our review of previous reports, in five patients given zoledronic acid with or without the protection of steroids, no additional ocular problems were reported [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Pamidronate was also prescribed to another patient, and a tolerance effect was also observed with a prior combination of steroids [<xref ref-type="bibr" rid="CR27">27</xref>]. Interestingly, our patient developed uveitis soon after administration of intravenous zoledronate after a 2-year tolerance to oral alendronate. This is the first report of ZAIU after long-term alendronate tolerance.</p>
      <p>Patel et al. retrospectively reported that 0.8&#xA0;% of postmenopausal women with osteopenia receiving zoledronate developed mild to severe anterior acute uveitis [<xref ref-type="bibr" rid="CR4">4</xref>]. More recently, the incidence of ZAIU was prospectively reported to be 1.1&#xA0;% [95&#xA0;% confidence interval (CI) 0.5&#x2013;2.1] in a secondary analysis of a randomized controlled trial of early postmenopausal women [<xref ref-type="bibr" rid="CR3">3</xref>]. Regarding oral bisphosphonates, a retrospective cohort study reported the incidence rate to be 29/10,000 person-years for uveitis in 10,827 first time users [<xref ref-type="bibr" rid="CR28">28</xref>]. The true incidence might be higher, because some mild to moderate patients may fail to seek treatment.</p>
      <p>APR is the most frequent adverse event after bisphosphonate use, usually including fever, fatigue, nasopharyngitis, musculoskeletal pain, and gastrointestinal symptoms. All APR components had a peak onset within 1&#xA0;day, and the median duration of the APR was 3&#xA0;days [<xref ref-type="bibr" rid="CR21">21</xref>]. Recently, acute uveitis is being considered as part of APR after bisphosphonate dispensing, due to its similar time of occurrence [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Bisphosphonates have been shown to share homologies with &#x3B3;/&#x3B4; T-cell ligands by stimulating cytokine release by &#x3B3;/&#x3B4; lymphocytes, and by inhibiting farnesyl diphosphate synthase to increase the intracellular accumulation of isopentenyl pyrophosphate [<xref ref-type="bibr" rid="CR29">29</xref>]. These activities may contribute to the development of APR and uveitis.</p>
      <p>Reid et al. investigated 7,765 postmenopausal women with osteoporosis, using a stepwise logistic regression analysis, and showed that APRs were less common in smokers, diabetics, calcitonin users, and previous oral bisphosphonate users [<xref ref-type="bibr" rid="CR21">21</xref>]. Because uveitis is a part of APR, it seems to develop less frequently after oral bisphosphonate tolerance, as described in our case study. Additional and larger case studies and single case reports are still needed to confirm the risk factors of ZAIU after previous bisphosphonate use.</p>
    </sec>
    <sec id="Sec5">
      <title>Conclusions</title>
      <p>We report a case of ZAIU with macular edema after long-term oral alendronate tolerance. ZAIU is beginning to be accepted as part of APR due to the similar time of occurrence. Endocrinologists and ophthalmologists should be aware of this drug reaction, in cases of deterioration of ocular symptoms and the inappropriate use of antibiotics and antiviral agents. Prior oral alendronate may not entirely prevent ZAIU. Steroids are usually necessary in the treatment of ZAIU, and systemic steroids are sometimes indicated. The readministration of bisphosphonate is not fully contraindicated, but according to the available evidence prior steroid protection may be a more reasonable treatment strategy.</p>
      <sec id="Sec6">
        <title>Consent</title>
        <p>Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>OCT</term>
          <def>
            <p>Optical coherence tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>ZAIU</term>
          <def>
            <p>Zoledronic acid induced uveitis</p>
          </def>
        </def-item>
        <def-item>
          <term>APR</term>
          <def>
            <p>Acute phase reaction</p>
          </def>
        </def-item>
        <def-item>
          <term>MGUS</term>
          <def>
            <p>Monoclonal gammopathy of undetermined significance</p>
          </def>
        </def-item>
        <def-item>
          <term>NOF</term>
          <def>
            <p>National Osteoporosis Foundation</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors&#x2019; declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>YT: drafted the manuscript and critically revised it for important intellectual content. RW, QL, and FY: in made the final diagnosis of the patient, and revised the manuscript critically for important intellectual content. LL: and CM: performed the systemic steroids treatment on the patient, and made substantial contributions to the acquisition of data. All authors read and approved the final manuscript.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; information</bold>
        </p>
        <p>Lianyuan Liu used to be a clinical doctor of the First Hospital of Qinhuangdao, now he is Chief of Liaison Office.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors would like to thank Dr. Dongni Yang for ophthalmological adjudication.</p>
      <p>None of the authors has received any funding related to this manuscript.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bobba</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Beattie</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Parkinson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kumbhare</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Adachi</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease</article-title>
          <source>Drug Saf</source>
          <year>2006</year>
          <volume>29</volume>
          <issue>12</issue>
          <fpage>1133</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="doi">10.2165/00002018-200629120-00005</pub-id>
          <pub-id pub-id-type="pmid">17147460</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>French</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Margo</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort</article-title>
          <source>Retina</source>
          <year>2008</year>
          <volume>28</volume>
          <issue>6</issue>
          <fpage>889</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.1097/IAE.0b013e31816576ef</pub-id>
          <pub-id pub-id-type="pmid">18536608</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patel</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Bolland</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nisa</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Al-Abuwsi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Horne</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial</article-title>
          <source>Osteoporos Int</source>
          <year>2015</year>
          <volume>26</volume>
          <issue>2</issue>
          <fpage>499</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1007/s00198-014-2872-5</pub-id>
          <pub-id pub-id-type="pmid">25187119</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patel</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Horne</surname>
              <given-names>A</given-names>
            </name>
            <collab>House M</collab>
            <name>
              <surname>Reid</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>McGhee</surname>
              <given-names>CN</given-names>
            </name>
          </person-group>
          <article-title>The incidence of acute anterior uveitis after intravenous zoledronate</article-title>
          <source>Ophthalmology</source>
          <year>2013</year>
          <volume>120</volume>
          <issue>4</issue>
          <fpage>773</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ophtha.2012.10.028</pub-id>
          <pub-id pub-id-type="pmid">23290982</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freitas-Neto</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>de Oliveira Fagundes</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>M</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Pacheco</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Freitas</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Avila</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
          <article-title>Unilateral Uveitis with Vitreous Haze Following Zoledronic Acid Therapy for Osteoporosis</article-title>
          <source>Semin Ophthalmol</source>
          <year>2013</year>
          <pub-id pub-id-type="pmid">24168214</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kordic</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Chaloupka</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Bisphosphonate-associated orbital inflammatory disease and uveitis anterior--a case report and review</article-title>
          <source>Klin Monbl Augenheilkd</source>
          <year>2013</year>
          <volume>230</volume>
          <issue>4</issue>
          <fpage>367</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0032-1328337</pub-id>
          <pub-id pub-id-type="pmid">23629782</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Albani-Campanario</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Buendia-Diaz</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Flores-Islas Mde</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Maquita-Nakano</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ochoa-Cervantes</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Zoledronic acid-based uveitis: a case report and a bibliography review</article-title>
          <source>Ginecol Obstet Mex</source>
          <year>2012</year>
          <volume>80</volume>
          <issue>5</issue>
          <fpage>355</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">23301428</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peterson</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Bedrossian</surname>
              <given-names>EH</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Bisphosphonate-associated orbital inflammation--a case report and review</article-title>
          <source>Orbit</source>
          <year>2012</year>
          <volume>31</volume>
          <issue>2</issue>
          <fpage>119</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.3109/01676830.2011.648818</pub-id>
          <pub-id pub-id-type="pmid">22489855</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Banal</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Briot</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ayoub</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dougados</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Roux</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer</article-title>
          <source>J Rheumatol</source>
          <year>2008</year>
          <volume>35</volume>
          <issue>12</issue>
          <fpage>2458</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.3899/jrheum.080273</pub-id>
          <pub-id pub-id-type="pmid">19040323</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kilickap</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ozdamar</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Altundag</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Dizdar</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>A case report: zoledronic acid-induced anterior uveitis</article-title>
          <source>Med Oncol</source>
          <year>2008</year>
          <volume>25</volume>
          <issue>2</issue>
          <fpage>238</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1007/s12032-007-9006-2</pub-id>
          <pub-id pub-id-type="pmid">18488162</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Beith</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer</article-title>
          <source>Med J Aust</source>
          <year>2008</year>
          <volume>188</volume>
          <issue>6</issue>
          <fpage>370</fpage>
          <lpage>1</lpage>
          <pub-id pub-id-type="pmid">18341464</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Woo</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Joseph</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Serious ocular complications of zoledronate</article-title>
          <source>Clin Oncol (R Coll Radiol)</source>
          <year>2006</year>
          <volume>18</volume>
          <issue>7</issue>
          <fpage>545</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1016/j.clon.2006.04.013</pub-id>
          <pub-id pub-id-type="pmid">16969985</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El Saghir</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Otrock</surname>
              <given-names>ZK</given-names>
            </name>
            <name>
              <surname>Bleik</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer</article-title>
          <source>BMC Cancer</source>
          <year>2005</year>
          <volume>5</volume>
          <fpage>156</fpage>
          <pub-id pub-id-type="doi">10.1186/1471-2407-5-156</pub-id>
          <pub-id pub-id-type="pmid">16332258</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Durnian</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Olujohungbe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kyle</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy</article-title>
          <source>Eye (Lond)</source>
          <year>2005</year>
          <volume>19</volume>
          <issue>2</issue>
          <fpage>221</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.eye.6701461</pub-id>
          <pub-id pub-id-type="pmid">15258605</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ryan</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Sampath</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic orbital inflammation following intravenous pamidronate</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2001</year>
          <volume>40</volume>
          <issue>8</issue>
          <fpage>956</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1093/rheumatology/40.8.956</pub-id>
          <pub-id pub-id-type="pmid">11511778</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Subramanian</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Kerrison</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Calvert</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>NR</given-names>
            </name>
          </person-group>
          <article-title>Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer</article-title>
          <source>Arch Ophthalmol</source>
          <year>2003</year>
          <volume>121</volume>
          <issue>9</issue>
          <fpage>1335</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1001/archopht.121.9.1335</pub-id>
          <pub-id pub-id-type="pmid">12963622</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mbekeani</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Slamovits</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Sauer</surname>
              <given-names>HL</given-names>
            </name>
          </person-group>
          <article-title>Ocular inflammation associated with alendronate therapy</article-title>
          <source>Arch Ophthalmol</source>
          <year>1999</year>
          <volume>117</volume>
          <issue>6</issue>
          <fpage>837</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">10369603</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fietta</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Manganelli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lodigiani</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Clodronate induced uveitis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2003</year>
          <volume>62</volume>
          <issue>4</issue>
          <fpage>378</fpage>
          <lpage>1</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.62.4.378</pub-id>
          <pub-id pub-id-type="pmid">12634250</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dalle Carbonare</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zanatta</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gasparetto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Valenti</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management</article-title>
          <source>Drug Healthc Patient Saf</source>
          <year>2010</year>
          <volume>2</volume>
          <fpage>121</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="doi">10.2147/DHPS.S6285</pub-id>
          <pub-id pub-id-type="pmid">21701624</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patel</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Horne</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mihov</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>McGhee</surname>
              <given-names>CN</given-names>
            </name>
          </person-group>
          <article-title>The Effects of Re-challenge in Patients with a History of Acute Anterior Uveitis Following Intravenous Zoledronate</article-title>
          <source>Calcif Tissue Int</source>
          <year>2015</year>
          <volume>97</volume>
          <issue>1</issue>
          <fpage>58</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="doi">10.1007/s00223-015-0015-4</pub-id>
          <pub-id pub-id-type="pmid">26001948</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reid</surname>
              <given-names>IR</given-names>
            </name>
            <name>
              <surname>Gamble</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Mesenbrink</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lakatos</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Characterization of and risk factors for the acute-phase response after zoledronic acid</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2010</year>
          <volume>95</volume>
          <issue>9</issue>
          <fpage>4380</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2010-0597</pub-id>
          <pub-id pub-id-type="pmid">20554708</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cavallasca</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Reyt</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>[Acute anterior uveitis associated with the use zoledronic acid]</article-title>
          <source>Medicina (B Aires)</source>
          <year>2014</year>
          <volume>74</volume>
          <issue>5</issue>
          <fpage>428</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">25347912</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Belliveau</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Urton</surname>
              <given-names>TE</given-names>
            </name>
          </person-group>
          <article-title>Acute anterior uveitis following zoledronic acid infusion for osteoporosis</article-title>
          <source>Can J Ophthalmol</source>
          <year>2012</year>
          <volume>47</volume>
          <issue>5</issue>
          <fpage>e22</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcjo.2012.03.020</pub-id>
          <pub-id pub-id-type="pmid">23036555</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rathnam</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Sagar</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Cyriac</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Acute uveitis following zoledronic acid infusion</article-title>
          <source>Oman J Ophthalmol</source>
          <year>2009</year>
          <volume>2</volume>
          <issue>2</issue>
          <fpage>102</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="doi">10.4103/0974-620X.53046</pub-id>
          <pub-id pub-id-type="pmid">20671842</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colucci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Modorati</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Miserocchi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Di Matteo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rama</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Anterior uveitis complicating zoledronic acid infusion</article-title>
          <source>Ocul Immunol Inflamm</source>
          <year>2009</year>
          <volume>17</volume>
          <issue>4</issue>
          <fpage>267</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1080/09273940902916111</pub-id>
          <pub-id pub-id-type="pmid">19657981</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cosman</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>de Beur</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>LeBoff</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Lewiecki</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Tanner</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Randall</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Erratum to: Clinician&#x2019;s guide to prevention and treatment of osteoporosis</article-title>
          <source>Osteoporos Int</source>
          <year>2015</year>
          <volume>26</volume>
          <issue>7</issue>
          <fpage>2045</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1007/s00198-015-3037-x</pub-id>
          <pub-id pub-id-type="pmid">25986381</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Birkholz</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>Another case of bisphosphonate-induced orbital inflammation</article-title>
          <source>J Neuroophthalmol</source>
          <year>2010</year>
          <volume>30</volume>
          <issue>1</issue>
          <fpage>94</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1097/WNO.0b013e3181c1a589</pub-id>
          <pub-id pub-id-type="pmid">20182217</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Etminan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Forooghian</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Maberley</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study</article-title>
          <source>CMAJ</source>
          <year>2012</year>
          <volume>184</volume>
          <issue>8</issue>
          <fpage>E431</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1503/cmaj.111752</pub-id>
          <pub-id pub-id-type="pmid">22470169</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hewitt</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Lissina</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Slay</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Sewell</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins</article-title>
          <source>Clin Exp Immunol</source>
          <year>2005</year>
          <volume>139</volume>
          <issue>1</issue>
          <fpage>101</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2249.2005.02665.x</pub-id>
          <pub-id pub-id-type="pmid">15606619</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
